Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Estetrol/Drospirenone for Ovarian Endometrioma

Endometriosis, a chronic gynecological disorder associated with pain and infertility, is a common condition affecting approximately one in ten women. Up to 50% of patients with endometriosis have ovarian endometriomas (or "chocolate cysts").

Official registry: https://clinicaltrials.gov/study/NCT05837624 · Andrew Zakhari · enrollment listed as 21

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Estetrol/Drospirenone. The registry lists allocation as na. Endometriosis, a chronic gynecological disorder associated with pain and infertility, is a common condition affecting approximately one in ten women.

They plan to enroll about 21 people at Montreal. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Estetrol/Drospirenone to Reduce the Average Size of Endometriomas

Interventions: Estetrol/Drospirenone

Primary outcome (registry wording): Change in ovarian endometrioma volume at 6-months (from baseline)

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Women only
  • Equal to or greater than 18 years old
  • Has at least one ovarian endometrioma, of at least 3 cm
  • Seeking a hormonal treatment for their endometrioma(s)

Public study contact (from the registry)

Andrew Zakhari, M.D.

5142288889

andrew.zakhari@mcgill.ca

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseScottsdale, Arizona
Not a traditional drug phase: Quality-of-Life Assessment for Cervical Carcinoma

This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy uses high energy protons or x-rays to kill tumor cells and shrink tumors.

NCT04567771 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingNot a traditional drug phaseChandler, Arizona
Not a traditional drug phase: Observational study, no intervention for Endometriosis

The goal of this watch-and-measure (no experimental treatment required) study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test

NCT05245695 · Official ClinicalTrials.gov record · Aspira Women's Health

FAQ about this NCT record

Is NCT05837624 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT05837624?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT05837624?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary